Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Polyrizon Ltd. (PLRZ) is a clinical-stage biotechnology company focused on the development of intranasal medical countermeasures designed to protect against radiological, nuclear, and biological threats. The company operates within the biodefense, emergency preparedness, and pharmaceutical development industries, with a primary emphasis on non-systemic, locally acting therapies. Its core technology platform is based on proprietary polymer-based formulations intended to create a physical barrier within the nasal cavity to prevent the absorption of harmful agents.
The company’s primary revenue drivers are research and development activities related to its lead product candidates, as Polyrizon does not currently generate commercial product revenue. Its target customers include government agencies, defense and homeland security organizations, and public health authorities seeking preventive solutions for civilian and military populations. Polyrizon positions itself uniquely by focusing on pre-exposure and post-exposure intranasal protection that is non-invasive and designed for rapid deployment. Founded in 2008 and headquartered in Israel, the company has evolved from an early-stage research entity into a publicly traded company listed on Nasdaq following its initial public offering in 2021.
Business Operations
Polyrizon’s operations are centered on a single operating segment: the research, development, and potential commercialization of intranasal polymer-based medical countermeasures. Its lead product candidate, PL-14, is being developed as a broad-spectrum nasal spray designed to reduce the risk of damage from radioactive particles and other inhaled threats. The company generates value through intellectual property development, preclinical studies, regulatory engagement, and clinical planning rather than product sales.
Operationally, Polyrizon conducts most of its research and development activities in Israel, while its corporate and capital markets activities are aligned with U.S. public company requirements. The company controls proprietary formulation technologies and related patents but relies on third-party manufacturers and research organizations for certain development activities. As of the most recent publicly available filings, Polyrizon does not report material joint ventures or revenue-generating subsidiaries.
Strategic Position & Investments
Polyrizon’s strategic direction is focused on advancing its intranasal platform toward regulatory approval, particularly for applications related to radiation exposure and biodefense preparedness. Growth initiatives center on progressing PL-14 through additional preclinical and clinical development stages, expanding potential indications, and pursuing non-dilutive funding opportunities, including government grants and strategic collaborations.
The company has not announced any transformative acquisitions but continues to invest in strengthening its intellectual property portfolio and formulation technologies. Polyrizon’s strategic positioning emphasizes emerging threats related to radiological and biological exposure, a niche segment within the broader pharmaceutical market that benefits from heightened global awareness of emergency preparedness. Its activities remain concentrated on internal development rather than operating a diversified portfolio of subsidiaries or investments.
Geographic Footprint
Polyrizon is headquartered in Israel, which serves as the center of its research, development, and management activities. The company maintains a public market presence in the United States through its Nasdaq listing, which supports access to international investors and capital markets.
While Polyrizon does not operate manufacturing or commercial facilities across multiple continents, its strategic focus is global in nature. The company’s target markets include North America, Europe, and other regions where governments and public health authorities invest in biodefense and emergency medical countermeasures. Its geographic influence is therefore driven more by intended end markets and regulatory engagement than by physical operational scale.
Leadership & Governance
Polyrizon is led by an executive team with experience in biotechnology, healthcare, and corporate governance. The leadership emphasizes a strategy focused on scientific validation, regulatory alignment, and long-term value creation through specialized medical countermeasures. Public disclosures describe a governance approach aligned with U.S. public company standards following its Nasdaq listing.
Key executives include:
- Isaac Bentwich – Chief Executive Officer
- David Elhadad – Chairman of the Board
Details regarding additional executive officers and senior management roles are limited in publicly available sources, and data inconclusive based on available public sources regarding a broader executive roster beyond those listed above.